Skip to content
DataLookout
Menu

NCT06929273

A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 33 versions: 33 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 182 → 191 locations
  2. Notable Eligibility criteria expanded, about 15 words
    • Study sites: 182 to 184
  3. Minor Trial sites expanded: 174 → 182 locationsv31
  4. Minor Study sites revised (174)v30
  5. Notable Eligibility criteria expanded, about 3 words
    • Study sites: 175 to 174
    v29
  6. Minor Trial sites expanded: 172 → 175 locationsv28
  7. Minor Study sites: 173 to 172v27
  8. Minor Study sites: 172 to 173v26
  9. Minor Study sites: 170 to 172v25
  10. Minor Study sites revised (170)v24
  11. Minor Study sites revised (170)v23
  12. Minor Study sites: 169 to 170v22
  13. Minor Study sites: 170 to 169v21
  14. Minor Study sites revised (170)v20
  15. Minor Study sites: 169 to 170v19
  16. Minor Study sites: 157 to 169v18
  17. Minor Study sites: 153 to 157v17
  18. Minor Study sites revised (153)v16
  19. Minor Study sites: 152 to 153v15
  20. Minor Study sites: 143 to 152v14
  21. Minor Study sites revised (143)v13
  22. Minor Study sites: 141 to 143v12
  23. Notable Enrollment target: 300 to 450v11 Show 4 more changesShow less
    • Eligibility criteria expanded, about 5 words
    • Interventions: KarXT (Drug) to KarXT (Drug), Lamotrigine (Drug), Lithium (Drug), Valproate (Drug)
    • Secondary endpoints revised (8)
    • Study sites revised (141)
  24. Minor Study sites: 129 to 141v10
  25. Minor Study sites revised (129)v9
  26. Minor Study sites: 126 to 129v8
  27. Minor Study sites: 125 to 126v7
  28. Minor Study sites: 124 to 125v6
  29. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 123 to 124
    • Start date changed from estimate of Jul 22, 2025 to Jul 18, 2025
    v5
  30. Minor Study sites: 122 to 123v4
  31. Minor Study sites: 119 to 122v3
  32. Minor Study sites: 110 to 119v2
  33. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Number of participants with treatment emergent adverse events (TEAEs)
Timeframe: Up to week 54

Secondary (8)

Number of participants with AEs of special interest (AESIs)
Number of participants with serious AEs (SAEs)
Number of participants with TEAEs leading to treatment discontinuation
Number of participants with change in suicidal ideation as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)
Change from baseline in Barnes Akathisia Rating Scale (BARS) score
Show 3 moreShow less
Change from baseline in Simpson Angus Scale (SAS) score
Change from baseline in Abnormal Involuntary Movement Scale (AIMS) score
Change from baseline in International Prostate Symptom Score (IPSS)

Arms and interventions

KarXT or Adjuvant KarXTExperimental

Drugs: KarXT, Lithium, Valproate, Lamotrigine

Sites

191 sites in 20 countries

United States 60, Japan 24, China 18, Ukraine 12, India 11, Romania 10, Bulgaria 8, Israel 8, Poland 6, Croatia 5, Italy 5, Argentina 4, France 3, Hungary 3, Slovakia 3, Spain 3, Sweden 3, Australia 2, Denmark 2, New Zealand 1